Comparative Pharmacology
Head-to-head clinical analysis: CERETEC versus INDIUM IN 111 OXYQUINOLINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CERETEC versus INDIUM IN 111 OXYQUINOLINE.
CERETEC vs INDIUM IN 111 OXYQUINOLINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Technetium-99m exametazime (Ceretec) is a lipophilic radiopharmaceutical that crosses the blood-brain barrier and is taken up by brain tissue in proportion to regional cerebral blood flow. Once inside cells, it undergoes intracellular conversion to a hydrophilic form, trapping it in the brain and allowing SPECT imaging.
Indium In 111 oxyquinoline is a radiolabeled compound that chelates indium-111 with oxyquinoline. The lipophilic complex penetrates cell membranes and binds to intracellular components, primarily in leukocytes (neutrophils). After intravenous injection, the radiolabeled cells accumulate at sites of inflammation or infection, allowing gamma camera imaging to detect focal areas of abnormal leukocyte localization.
555-740 MBq (15-20 mCi) intravenously as a single dose for SPECT imaging.
1-2 mCi (37-74 MBq) labeled autologous leukocytes, administered intravenously over 1-2 minutes.
None Documented
None Documented
Terminal: 6 hours (range 4–8 h); clinical: supports twice-daily dosing in nuclear medicine studies.
Terminal elimination half-life is approximately 4-6 hours for the free indium ion, but biological half-life for labeled cells can be 1-2 days depending on cell type.
Renal: 40% unchanged; biliary/fecal: 60% (as metabolites and parent compound).
Renal excretion approximately 70-80% within 24 hours; fecal excretion less than 5%.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical